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The present study aimed to evaluate the effect of alcohol (PA) and hydroalcohol (PHA) extract
of Paeonia emodi Royale roots in treatment of streptozotocinenicotinamide induced diabetic
nephropathy. Diabetes mellitus was induced inmaleWistar rats by streptozotocin (65mg/kg
intraperitoneally) 15 minutes after nicotinamide (230 mg/kg, intraperitoneally) administra-
tion and diabetic nephropathy was assessed by measuring serum glucose, renal parameters
(urea, uric acid, creatinine, and blood urea nitrogen level) and lipid profile. The rats were
treated with different doses of extracts (100 mg/kg, 200 mg/kg, and 400 mg/kg) for 45 days.
Oxidative stress was assessed bymeasuring tissue antioxidant enzymes level along with the
formation of advanced glycation end-products (AGEs) in kidney. PA and PHA (400 mg/kg)
produced significant attenuation in the serum glucose level (165.08 ± 3.353 mg/dL and
154.27 ± 2.209 mg/dL, respectively) as compared to control. Elevated renal parameters, lipid
levels, tissueantioxidant enzymesandAGE formationwerealso restored inadose-dependent
manner. These findings suggest that by amelioration of oxidative stress and formation of
AGEs, PA and PHA significantly inhibited the progression diabetic nephropathy in rats.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetic nephropathy (DN) is one of the major complications
of diabetes mellitus, and the morbidity and mortality due to
this disease are constantly progressing in industrialized na-
tions. If left untreated, 20e40% of diabetic patients with
microalbuminuria will progress to overt nephropathy and 20%
of them will develop end-stage renal failure within 20 years.rmacy, M.M. University, M
ail.com (R. Singh).
inistration, Taiwan. Publis
/licenses/by-nc-nd/4.0/).
L, et al., Nephroprotective
cinenicotinamide induceDN is characterized by initial oxidative stress, inflammatory
response, thickening of basement membranes, expansion of
mesangial matrix and interstitial fibrosis, podocyte and renal
cell death, increased albuminuria, and renal dysfunction [1].
Chronic hyperglycemia eventually leads to the irreversible
formation of long-lived nonenzymatic glycated proteins,
known as advanced glycation end-products (AGEs), in serum
and tissues. These play an important role in the development
of DN [2]. Moreover, hyperglycemia induces oxidative stress inullana-Ambala, Haryana 133207, India.
hed by Elsevier Taiwan LLC. This is an open access article under the CC
effect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
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biochemical pathways such as glucose flux through the polyol
pathway, the hexosamine pathway, excess/inappropriate
activation of protein kinase C isoforms and accumulation of
AGEs. While activation of each pathway may be injurious
alone, collectively they cause an imbalance in the mitochon-
drial redox state of the cell and lead to excess formation of
reactive oxygen species (ROS). These activated pathways are a
major source of damage and are potential therapeutic targets
in DN [3]. Herbs are a mine of medicinal agents and many
medicinal herbs are found to be efficacious, cheap, and safe in
preventing diabetes and diabetic complications. Moreover,
use of herbal medicines for the treatment of diabetic compli-
cations is very important in developing countries where the
cost of conventional medicines is a burden to the population.
More than 30% of all plant species, at one time or another,
were used for medicinal purposes [4].
Paeonia emodi Royle (Paeoniaceae) is an erect glabrous, leafy
perennial herb indigenous to north-west Himalayas from
Kashmir to Kumaon commonly known as Ood-saleeb [5,6].
Several phytochemical studies have revealed that the root
contains monoterpene glycosides [7], monoterpene galacto-
sides (paeonin A, B, and C) [8], triterpene (emodinol) [9], 1,5-
dihydroxy-3-methyl-anthraquinone, ethyl gallate, and
methyl grevillate [10]. Various component of plant root
showed b-glucouronidase inhibitory activity [10], lip-
oxygenase inhibiting activity, hydroxyl radical scavenging
activity, neuroprotection [11], and anticonvulsant activities
[12,13]. Paeoninol from themethanolic extract of the fruit of P.
emodi [14] and a novel b-glucuronidase inhibiting triterpene
[1b, 3b, 5a, 23, 24-pentahydroxy-30-norolean-12, 20(29)-dien-
29-oic acid] have also been isolated from the plant [10]. Root
powder of the plant is used with Selinum vaginatum in folk
medicine recipe for the treatment of diabetes [15] So the pre-
sent study was undertaken to assess the protective effects of
alcohol (PA) and hydroalcohol (40%: PHA) extracts of roots of P.
emodi Royle in DN rats via inhibition of oxidative stress and
AGEs. To the best of our knowledge, this is first report on
nephroprotective effect of Paeonia emodi in streptozotocin
(STZ)-induced diabetic nephropathy.2. Methods
2.1. Animals
Adult male Wistar rats weighing 250e300 g were housed in
standard environmental conditions maintained at 23 ± 2C
with 12 hour lightedark cycle. Animals were fed standard
rodent diet andwater. Experimental protocol was approved by
Institutional Animal Ethical Committee (MMCP/IAEC/13/09)
and the experiments were performed according to the Com-
mittee for the Purpose of Control And Supervision of Experi-
ments on Animals (CPCSEA) guidelines.
2.2. Collection of plant material
Roots of P. emodi were procured from Green Earth Pvt. Ltd.
(New Delhi, India) in May, 2013 and identified by Dr Sunita
Garg (NISCAIR, New Delhi, India). A voucher specimenPlease cite this article in press as: Kishore L, et al., Nephroprotective
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http://dx.doi.org/10.1016/j.jfda.2016.08.009(NISCAIR/RHMD/Consult/2013/2296/76) was deposited in the
herbarium of NISCAIR for future reference. The botanical
name of the plant was verified from published literature and
database [16,17].
2.3. Preparation of extract
The roots were dried in the shade, powdered, and then used
for the extraction of potential antidiabetic constituents into
different solvents (petroleum ether, chloroform, ethanol, and
hydroalcohol). Roots were sequentially extracted with sol-
vents in order of increasing polarity, i.e., petroleum ether
60e80C, chloroform, ethanol, and hydroalcohol (40%) by
Soxhlet extraction method. The extraction procedure was
continued until the extract gave no coloration. The extracts
were distilled and concentrated under reduced pressure and
finally freeze dried. PA and PHA extracts were used for further
studies.
2.4. Chemicals
STZ was obtained from SigmaeAldrich (Milwaukee, WI, USA)
and nicotinamide (NAD) from Finar India Ltd. Diagnostic kits
for the biochemical estimations were obtained from Reckon
Diagnostics Pvt. Ltd. (Vadodara, Gujarat, India). All the other
chemicals used were of analytical grade.
2.5. Phytochemical screening
The PA and PHA were used to test the chemical compounds
suchas alkaloids, carbohydrates, fixedoils and fats, terpenoids,
phenols, tannins, glycosides, saponins, proteins, amino-acids,
and flavonoids in accordance with the methods of Trease and
Evans [18], Harbourne [19] with slight modifications. Phyto-
chemical profile ofPAandPHAwasalsodeterminedusinghigh-
performance thin layer chromatography (HPTLC) fingerprinting
techniques on an automated HPTLC system (CAMAG, Muttenz,
Switzerland) according to the instructions of themanufacturer.
The developed plates were air dried and viewed in ultraviolet
radiations and then scanned by Densitometer (CAMAG TLC
Scanner) at 254 nm and 366 nm. The Rf values and fingerprint
data were obtained using WIN CATS software (CAMAG, Mut-
tenz, Switzerland).
2.6. Quantitative analysis
2.6.1. Determination of total flavonoids
A 10-g sample of root powder was extracted repeatedly with
100 mL of 80% aqueous methanol at room temperature. The
whole solution was filtered through Whatman filter paper No.
42. The filtrate was later transferred into a crucible and evap-
orated into dryness and weighed to a constant weight [20].
2.6.2. Terpenoid extraction
A50-g sampleof thepowdered rootswas extractedwith solvent
combination of methanol and water (4:1) at room temperature
for 24 hours. The solution was filtered using Whatman filter
paper No. 1 and the filtratewas then evaporated to 1/10 volume
at 40C. The remaining filtrate was acidified with 2M sulfuric
acid (pH 0.89) followed by chloroform extraction (3 times theeffect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
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Out of the two layers formed, the nonaqueous layer was taken
and evaporated until dryness. The dried extract contained ter-
penoids [19].
2.7. Experimental design and animals
Adult male Wistar rats, procured from NIPER (Mohali, India)
with initial weights of 280e300 g, were used in this study. Rats
were housed under normal conditions with a 12-hour light/
dark cycle at 23 ± 1C and 40% humidity. Animals were fed
standard rodent chow and water.
Diabetes was induced by STZ intraperitoneally at a dose of
65mg/kg (dissolved in pH 4.5 citrate buffer immediately before
injection) 15 min after NAD (230 mg/kg, intraperitoneally).
Induction of the diabetes was confirmed by measuring fasting
blood glucose levels 72 hours after STZ-NAD injection. The
rats with fasting blood glucose level  250 mg/dL were
included in the study. Different doses of the extracts (100 mg/
kg, 200 mg/kg, and 400 mg/kg) were selected on the basis of
oral acute toxicity studies reported in the literature [21]. As DN
symptoms typically develop after 30e45 days, the levels of
serum urea, uric acid, creatinine, and blood urea nitrogen
(BUN) was estimated on the 30th day. Elevated levels of serum
urea, uric acid, creatinine, and BUN suggest development of
DN. Then treatment with extract and standard was continued
for a further 45 days.
Animals were divided into nine groups consisting of six
rats each. Group 1 was normal control; Group 2 was DN con-
trol; in Groups 3e5, DN rats were treated with 100 mg/kg,
200 mg/kg, or 400 mg/kg PA, respectively; in Groups 6e8 DN
rats received 100 mg/kg, 200 mg/kg, or 400 mg/kg PHA,
respectively; and Group 9 consisted DN rats receiving 10 mg/
kg glimepride.
Blood glucose level, body weight, glycated hemoglobin
(Hb1Ac), lipid profile, renal function tests were estimated on
the 30th day, 45th day, 60th day, and 75th day after STZ induc-
tion. Biochemical estimation was carried out using commer-
cially available kits of Reckon Diagnostics. Liver, kidney and
pancreas were obtained and stored at 70C until use for
histopathological examination.
2.8. Body weight and blood glucose estimation
The body weight of each animal was measured before
administration of STZ-NAD and animals with similar weight
were grouped together. Body weight of each group was
measured periodically till end of study. Fasting blood glucose
level was estimated after 72 hours of STD administration to
confirm diabetes and then at interval of 15 days using com-
mercial enzymatic kits purchased from Reckon Diagnostics
Pvt. Ltd. INDIA throughout the study.
2.9. Lipid profiles assay
Serum total cholesterol (TC), triglycerides (TG), low density
lipoproteins (LDL), very low density lipoproteins (VLDL), and
high density lipoproteins (HDL) were measured on the
30th day, 45th day, 60th day, and 75th day using commercial
enzymatic kits purchased from Reckon Diagnostics.Please cite this article in press as: Kishore L, et al., Nephroprotective
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Blood samples were collected on the 30th day, 45th day,
60th day, and 75th day from DN control and treated rats for the
estimation of serum creatinine, urea, uric acid and BUN using
commercial enzymatic kits (Reckon Diagnostics). The animals
were placed in individual metabolic cages for 12 hours to
collect urine samples before the experimental rats were killed.
Urinary creatinine and albumin excretion (UAE) were
assessed using kits from Reckon Diagnostics. Creatinine
clearance was calculated according to the standard formula:
Ccr (mL/min/100 g body weight) ¼ [urinary creatinine (mg/
mL)  urine volume (mL)/serum creatinine (mg/mL)]  [100/
body weight (g)]  [1/720 (min)]. (1)
2.11. Estimation of antioxidant enzyme levels
Tissue (kidney, pancreas, and liver) homogenate was used to
estimate thiobarbituric acid reactive substances (TBARS) [22]
and level of antioxidant enzymes superoxide dismutase
(SOD) and reduced glutathione (GSH).
2.12. AGE estimation in kidneys
AGE levels in the kidneys were determined by a method as
previously described by Sensi et al [23]. Briefly, perfused kid-
neys were homogenized in 2 mL of 0.25M sucrose followed by
centrifugation at 900g at 5C and the supernatant was sepa-
rated. The pellet was re-suspended in 2 mL sucrose solution
and centrifuged and the supernatant obtained was mixed
with the previous one. The proteins present were precipitated
by adding equal volume of trichloroacetic acid. Following
centrifugation at 4C at 900g, the protein pellet obtained was
mixed with 1 mL methanol twice to remove the lipid fraction.
The insoluble protein, after washing with 10% cooled tri-
chloroacetic acid was centrifuged and the residue was solu-
bilized in 1 mL of 1N NaOH and the protein concentration was
estimated by measuring the absorbance at 280 nm against
BSA standard curve. The AGE content was then measured
fluorometrically with an emission at 440 nm and excitation at
370 nm, and the results were expressed as relative fluores-
cence units (RFU)/mg protein.
2.13. Histopathology
Liver, kidney, and pancreatic tissues were obtained from the
sacrificed animals and fixed in 10% neutral buffered formalin
solution, dehydrated in ethanol and embedded in paraffin.
Sections of 5 mmwere prepared using a rotary microtome and
stained with hematoxylin and eosin for microscopic
observations.
2.14. Statistical analysis
Statistical analysis was performed using Graphpad Prism 6
(GraphPad Software, Inc., California Corporation). Valueswere
expressed asmean± standard error of themean, and one-way
analysis of variance (ANOVA) was used for statistical analysis.effect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
Table 1 e High-performance thin layer chromatography
fingerprinting profile of Paeonia emodi.
Sample
No.
Rf values
Alcohol extract
of P. emodi
Hydro-alcohol extract
of P. emodi
254 nm 366 nm 254 nm 366 nm
1. 0.21 0.29 d 0.09
2. 0.40 0.51 d 0.32
3. 0.69 0.94 d 0.67
4. 0.76 1.27 d 0.87
5. 1.03 1.38 d 0.94
6. 1.18 d d d
7. 1.28 d d d
8. 1.37 d d d
j o u r n a l o f f o o d and d ru g an a l y s i s x x x ( 2 0 1 6 ) 1e1 34ANOVA was followed by Tukey's as post hoc multiple compar-
ison test. The results were considered significant if p  0.05.3. Results
3.1. Phytochemical screening
Preliminary phytochemical screening of PA showed the pres-
ence terpenoids and phenolic compounds whereas poly-
phenolic compounds, flavonoids, tannins, and terpenoidswere
present in PHA. HPTLC fingerprinting of the plant extracts is
presented in Table 1, which confirms the presence of different
types of phytochemical compounds in the PA and PHA. The
presence of bands of different Rf values indicated the occur-
rence of several phytochemicals in the extract of P. emodi.
3.2. Quantitative analysis
The quantity of flavonoids and terpenoids was found in the
following order 12.70% > 4.12%, respectively.Figure 1 e Effect of alcohol (PA) and hydroalcohol (PHA) extract
analyzed by using one-way analysis of variance followed by Tu
mean ± standard error of the mean (n¼ 6). * p < 0.001. ** p < 0.05
P. emodi extract 100 mg/kg.
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DN control rats showed significant attenuation in bodyweight
during the study. Administration of PA at doses of 100 mg/kg,
200 mg/kg, and 400 mg/kg increased the body weight signifi-
cantly by 5.74%, 9.13%, and 12.91%, respectively. PHA
increased the body weight by 5.18%, 10.04%, and 13.87%,
respectively, at doses of 100mg/kg, 200mg/kg, and 400mg/kg.
Glimepride also increased the body weight by 18.36% in DN
rats (Figure 1). The effect on body weight was found to be dose
dependent in treatment groups. Food and water intake in
diabetic rats significantly increased compared with the
normal rats. Chronic treatment with PA and PHA significantly
ameliorated these physiological parameters.3.3. Effect of PA and PHA on blood glucose
STZ-NAD administration resulted in significant increase in
fasting blood glucose of diabetic rats with time, when
compared to nondiabetic rats. Treatment of diabetic rats with
the extract reduced the blood glucose level in a dose-
dependent manner. A significant reduction in fasting blood
glucose level was observed in DN rats treatedwith PA and PHA
(400 mg/kg) from initial level of 324.49 mg/dL to 165.08 mg/dL
and of 327.75 mg/dL to 154.27 mg/dL, respectively (Figure 2).
The results of PHA at a dose of 400 mg/kg were comparable to
that of glimepride (10 mg/kg) that reduced blood glucose level
up to 130.41 mg/dL at the end of the study.3.4. Effect of PA and PHA on HbA1c
Hb1Ac level wasmeasured at the start of treatment and end of
the study. Substantial elevation in Hb1Ac level was observed
in untreated DN control group (8.20 ± 0.06%) in comparison to
normal control (4.02 ± 0.029%) on the 30th day and the level of
Hb1Ac was further increased in DN rats at the end of studys of Paeonia emodi Royale roots on body weight. Data were
key's multiple test. Values are represented as
. a¼ versus control, b¼ versus diabetic control, c ¼ versus
effect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
Figure 2 e Effect of alcohol (PA) and hydroalcohol (PHA) extracts of Paeonia emodi Royale roots on blood glucose level. Data
were analyzed by using one-way analysis of variance followed by Tukey's multiple test. Values are represented as
mean ± standard error of the mean (n¼ 6). * p < 0.001. ** p < 0.01. *** p < 0.05. a¼ versus control, b¼ versus diabetic control,
c ¼ versus P. emodi extract 100 mg/kg, d ¼ versus P. emodi extract 200 mg/kg.
j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e1 3 5(75th day) to 11.01 ± 0.03%. After treatment with PA and PHA
(100 mg/kg, 200 mg/kg, and 400 mg/kg) for 45 days produced
significant decrease in Hb1Ac level in comparison to DN
control group, i.e., Hb1Ac level 6.56 ± 0.21%, 5.46 ± 0.07%,
4.77 ± 0.16% (PA), respectively, and 6.54 ± 0.18%, 5.38 ± 0.085%,
4.98 ± 0.07% (PHA), respectively.
3.5. Effect of PA and PHA on fasting insulin level
A significant decrease in fasting insulin level (5.64 ± 0.17 mU/
mL) was observed in STZ- treated diabetic nephropathy rats in
comparison to normal control rats (14.84 ± 0.41 mU/mL).Figure 3 e Effect of alcohol (PA) and hydroalcohol (PHA) extract
analyzed by using one-way analysis of variance followed by Tu
mean ± standard error of the mean (n¼ 6). * p < 0.001. ** p < 0.01
c ¼ versus P. emodi extract 100 mg/kg, d ¼ versus P. emodi extr
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products and oxidative stress in streptozotocinenicotinamide induce
http://dx.doi.org/10.1016/j.jfda.2016.08.009Administration of 100 mg/kg, 200 mg/kg, and 400 mg/kg of PA
and PHA for 45 days produced significant increase in serum
insulin level [PA (8.80 ± 0.24 mU/mL, 10.13 ± 0.23 mU/mL, and
11.38 ± 0.14 mU/mL, respectively); PHA (9.51 ± 0.30 mU/mL,
10.71 ± 0.18 mU/mL, and 12.94 ± 0.20 mU/mL, respectively;
Figure 3].
3.6. Effect of PA and PHA on renal function
UAE was found to be increased in DN control rats to a signif-
icant extent (1640.25 ± 0.93 mg/24 hours) in comparison to
normal control (219.66 ± 0.32 mg/24 hours). Administration ofs of Paeonia emodi Royale roots on insulin level. Data were
key's multiple test. Values are represented as
. *** p < 0.05. a¼ versus control, b¼ versus diabetic control,
act 200 mg/kg.
effect of Paeonia emodi via inhibition of advanced glycation end
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Table 2e Effect of alcohol (PA) and hydroalcohol (PHA) extracts of Paeonia emodi Royale roots on renal function estimation in
diabetic-nephropathy Wistar rats.a
Parameters Urea (mg/dL) Uric acid (mg/dL) Creatinine (mg/dL)
Groups 30th day 75th day 30th day 75th day 30th day 75th day
Normal 33.15 ± 0.789 33.28 ± 0.629 5.22 ± 0.216 5.27 ± 0.198 0.72 ± 0.009 0.81 ± 0.009
Diabetic control 82.13 ± 1.64a* 97.96 ± 0.518a* 12.59 ± 0.854a* 16.04 ± 0.612a* 2.83 ± 0.046a* 4.22 ± 0.062
PA 100 mg/kg 88.60 ± 1.616b*** 60.97 ± 0.447b*d** 11.85 ± 0.340 8.20 ± 0.142b* 3.48 ± 4.106b*** 2.05 ± 0.050b*
PA 200 mg/kg 89.04 ± 1.097 55.87 ± 1.774b*c** 12.16 ± 0.336 7.04 ± 0.120b* 3.63 ± 2.05b** 1.79 ± 0.064b*
PA 400 mg/kg 81.48 ± 0.673c**d** 43.08 ± 0.803b*c*d* 13.49 ± 0.273 6.11 ± 0.124b*c* 3.18 ± 1.795 1.05 ± 0.013b*c*d*
PHA 100 mg/kg 85.17 ± 1.546 61.56 ± 0.588b*d* 11.72 ± 0.303 8.05 ± 0.052 4.32 ± 1.058b* 2.32 ± 0.058b*
PHA 200 mg/kg 80.95 ± 1.469 51.96 ± 0.801b*c* 12.99 ± 0.330 7.10 ± 0.101b* 3.88 ± 2.321b* 1.97 ± 0.066b*
PHA 400 mg/kg 84.96 ± 1.636 40.92 ± 0.759b*c*d* 12.81 ± 0.370 6.34 ± 0.139b*c** 3.20 ± 1.978c* 1.10 ± 0.054b*c*d*
Glimipride 10 mg/kg 83.87 ± 1.098 34.35 ± 0.933b* 12.29 ± 0.634 6.01 ± 0.167b* 3.00 ± 0.223 0.96 ± 0.052b*
* p < 0.001.
** p < 0.01.
*** p < 0.05.
a ¼ versus control, b ¼ versus diabetic control, c ¼ versus P. emodi extract 100 mg/kg, d ¼ versus P. emodi extract 200 mg/kg.
a Each group (n ¼ 6) represents mean ± standard error of the mean. Data were analyzed by using one-way analysis of variance followed by
Tukey's multiple test.
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cantly reduced UAE to 496.52 ± 5.38 mg/24 hours,
483.81 ± 5.84 mg/24 hours, and 475.05 ± 9.17 mg/24 hours (PA);
503.9 ± 10.45 mg/24 hours, 476.02 ± 10.13 mg/24 hours, and
462.60 ± 5.18 mg/24 hours (PHA) respectively at 75th day. In DN
control rats a significant increase in urea (97.96 ± 0.52 mg/dL),
uric acid (15.54 ± 0.66 mg/dL), creatinine (4.10 ± 0.12 mg/dL),
and BUN (45.74± 0.24mg/dL) levels was observed at 75th day of
study in comparison to normal control. Administration of PA
and PHA (100 mg/kg, 200 mg/kg, and 400 mg/kg) attenuated
the increased renal parameters in a dose-dependent manner
(Table 2). Increased kidney weight/body weight ratio was
significantly ameliorated by the treatment with PA and PHA.
Twelve-hour urine volume and urinary creatinine increased
significantly increased in diabetic control rats in comparison
to normal control. Treatment with PA and PHA (100 mg/kg,
200 mg/kg, and 400 mg/kg) significantly reduced the level of
urine volume and urine creatinine level. In addition, treat-
ment with PA and PHA significantly improved creatinine
clearance (Table 2).3.7. Effect of PA and PHA on lipid profile
Serum TC, TG, LDL, and VLDL were found to be significantly
increased in DN rats. Administration of PA, PHA and gli-
mepride significantly reduced these levels. At the 75th day of
study PA, PHA (400 mg/kg), and glimepride showed similar
results in ameliorating TC level by 104.85 mg/dL, 105.42 mg/
dL, and 102.54 mg/dL, respectively. TG levels were reduced
by 35.06%, 41.17%, and 52.98% with administration of PA at
100 mg/kg, 200 mg/kg, and 400 mg/kg, respectively. PHA at
same doses reduced TG levels by 31.32%, 40.12%, and
49.68%, respectively. Similarly, levels of LDL and VLDL were
also reduced significantly by administration of PA, PHA, and
glimepride in DN rats. HDL-cholesterol significantly
decreased in DN rats and the treatment with PA, PHA, and
glimepride significantly increased the level of HDL-
cholesterol (Table 3).Please cite this article in press as: Kishore L, et al., Nephroprotective
products and oxidative stress in streptozotocinenicotinamide induce
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lipid peroxidation
GSH level was significantly decreased in kidney, liver, and
pancreas of DN rats. Treatment with PA and PHA for 45 days
increased level of antioxidant enzyme in comparison to DN
control group. Similar level of SOD was also reduced signifi-
cantly in DN rats. Intervention with PA and PHA increased
these levels significantly in kidney, liver, and pancreas.
Oxidative stress increases in DN due to increased lipid per-
oxidation and decreased level of antioxidant enzymes. Lipid
peroxidation in term of TBARS was found to be high in case
of DN control rats in comparison to normal control group
(Table 4).3.9. Effect of PA and PHA on AGEs in kidneys
Induction of DN in rats led to a significant increase in kidney
AGE levels when compared to normal animals. Administra-
tion of PA and PHA (100 mg/kg, 200 mg/kg, and 400 mg/kg)
significantly reduced (p < 0.001) the AGE levels in kidneys
when compared to control group. However, administration of
glimepride (10 mg/kg) also produced significant change
(p < 0.05) in AGE levels when compared to the control group
(Figure 4).3.10. Histopathology
Kidney of normal control animals showed normal renal pa-
renchyma with renal glomeruli as a glomerulus and Bow-
man's capsule and surrounded by proximal and distal tubules.
Kidney of DN rats showed mesangial expansion and thick-
ening of glomerular capillaries. Glomeruli infiltrated by
inflammation cells along with infiltration were seen in the
cortex and medulla areas. Atrophy of glomeruli was seen in
STZ-induced diabetic rats. In the glimepiride-treatment
group, necrotic condition was reduced in convoluted tubules
with reduced infiltration of inflammation cells in cortex andeffect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
BUN (mg/dL) Urine output (mL) Urine creatinine (mg/dL) Creatinine clearance (mL/min/kg)
30th day 75th day 30th day 75th day 30th day 75th day 30th day 75th day
15.48 ± 0.368 15.54 ± 0.294 14.77 ± 0.763 15.44 ± 0.575 0.07 ± 0.016 0.08 ± 0.012 3.28 ± 0.238 3.05 ± 0.065
38.35 ± 0.769a* 45.74 ± 0.242a* 85.40 ± 1.614a* 86.90 ± 0.941a* 0.04 ± 0.018a* 0.04 ± 0.007a* 4.79 ± 0.381a** 3.75 ± 0.179
41.38 ± 0.751b*** 28.47 ± 0.207b*d** 83.29 ± 1.710 54.62 ± 1.440b* 0.04 ± 0.012 0.05 ± 0.009b* 3.50 ± 0.228 3.63 ± 0.147
41.58 ± 0.510b*** 26.09 ± 0.825b*c** 84.25 ± 1.058 52.75 ± 0.796b* 0.04 ± 0.007 0.06 ± 0.011b* 3.56 ± 0.167 4.03 ± 0.244
38.05 ± 0.313 20.12 ± 0.373b*c*d* 85.19 ± 1.263 45.19 ± 1.263b*c* 0.04 ± 0.017 0.06 ± 0.008b*c* 3.96 ± 0.090 6.75 ± 0.530b*c*
39.77 ± 0.719 28.74 ± 0.273b*d* 85.79 ± 1.520 44.62 ± 1.440b* 0.04 ± 0.024 0.05 ± 0.008b* 3.07 ± 0.261 4.78 ± 0.151
37.80 ± 0.683 24.26 ± 0.372b*c* 85.58 ± 0.862 41.08 ± 1.486b*e*** 0.04 ± 0.017 0.06 ± 0.011b*c** 3.39 ± 0.137 5.40 ± 0.281b***
39.69 ± 0.760 19.11 ± 0.353b*c*d* 85.19 ± 1.211 35.19 ± 1.263b*c**e* 0.05 ± 0.002 0.07 ± 0.001b*c* 4.33 ± 0.336 8.49 ± 0.473b*c*
39.01 ± 0.512 16.04 ± 0.477b* 85.20 ± 1.633 50.53 ± 1.070b* 0.04 ± 0.016 0.06 ± 0.009b* 4.19 ± 0.324 8.93 ± 0.386b*
j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e1 3 7medulla. P. emodi extracts treated group also showed protec-
tion, i.e. reduction in mesangial expansion, membrane
thickness and atrophy (Figure 5).
Normal central vein with radiating sinusoid cords was
present in liver of normal rats. There was no sinusoid
congestion, swelling, or necrotic cells. DN rats demonstrated
perivenular inflammatory collection and hyperplasia of
Kupffer cell with condensed nuclei and fatty infiltration.
These pathological changes were reversed by P. emodi extracts
administered DN rats (Figure 6).
Pancreatic cells of the normal control group showed
normal architecture with normal acini and islets cells with no
signs of edema or inflammation. In DN rats, inflammation,
disorganization of the islets and steatosis were observed. Cell
infiltration was seen in the acinar cells along with necrosis
and shrinkage of islet cells. Treatment with P. emodi extracts
and glimepride, showed protective effect on islets of Langer-
hans and acinar cells as compared to diabetic rats and further
reduction in edema, inflammation, and shrinkage of islets
(Figure 7).4. Discussion
STZ-induced diabetes in rats has been described as a useful
experimental model to study DN. The selective destruction of
pancreatic b-cells by STZ leads to the poor sensitivity of in-
sulin for glucose uptake [24]. NAD is an antioxidant that exerts
a protective effect on the cytotoxic action of STZ by scav-
enging free radicals and causes lesser damage to pancreatic b-
cell mass producing type 2 diabetes [25]. Chronic exposure to
hyperglycemia leads to activation of multiple biochemical
pathways including polyol pathway. Activation of these
pathways leads to generation of ROS, causing oxidative stress,
defective insulin gene expression, and increased apoptosis of
b-cells [26].
Sustained hyperglycemia is an important factor in medi-
ating the development and progression of diabetic kidney
disease [27e29]. Kidneys remove metabolic wastes such as
urea, uric acid, creatinine, and ions in order to maintain op-
timum chemical composition of body fluids. The concentra-
tions of the metabolites increase in blood during renal
diseases or renal damage associated with uncontrolled dia-
betesmellitus [30]. DN is characterized by an increase in blood
urea, uric acid, creatinine, and BUN level.Please cite this article in press as: Kishore L, et al., Nephroprotective
products and oxidative stress in streptozotocinenicotinamide induce
http://dx.doi.org/10.1016/j.jfda.2016.08.009The relationship between oxidant generation, oxidative
stress, hyperglycemia, and dyslipidemia is well known [31].
Lipids play an important role in the pathogenesis of compli-
cations associated with diabetes mellitus. Dyslipidemia could
lead to DN via activation of TGF-b pathway, subsequently
accelerating the production of ROS leading to glomerular
damage [32]. Moreover, increased polyol pathway activity
induced by hyperglycemia has been reported to contribute to
abnormalities such as increased osmotic and oxidative stress
factors that have been cited as promoters of diabetic micro-
vascular diseases, including DN [33]. Although complete
treatment of DN is not achievable, attenuation of hypergly-
cemia and oxidative stress associated with DN can ameliorate
the progression of diabetic complications.
Since diabetes has been known as an oxidative stress dis-
order caused by an imbalance between free radical formation
and the ability of the body's natural antioxidants, many
studies have suggested that oxidative stress can play a role in
systemic inflammation, endothelial dysfunction, impaired
secretion of pancreatic b-cells and impaired glucose utiliza-
tion in peripheral tissues [34], that lead to long-term second-
ary complications. Numerous epidemiological studies suggest
that herbs/diets rich in phytochemicals and antioxidants
execute a protective role in health and disease [35]. P. emodi
Royle is a traditional herb used for the management of dia-
betes which supported our present study [36]. Phytochemical
evaluation of PA and PHA showed the presence of terpenoids,
phenolic compounds including flavonoids, and tannins. Out of
these, PA was found to be rich in phenolic compounds
whereas PHA contained abundant terpenoids. Previous
studies showed the presence of triterpenoids in P. emodi,
which include emodinol [8],1b,3 b,5a,23,24-pentahydroxy-30-
nor-olean-12,20(29)-dien-28-oic acid [10], 6a,7a-epoxy-
1a,3b,4b,13b- tetrahydroxy-24,30-dinor-olean-20-ene-28,13 b-
olide,1a, 3b,4b -trihydroxy-24,30-dinor-olean-6-ene-28-oic
acid,11a,12a -epoxy-3b,4b,-dihydroxy-24-nor-olean-28-oic
acid, 3b,4b,23,30-tetrahydroxy-24-nor-olean-12-ene-28-oic
acid [37], oleanolic acid, betulinic acid [10], b-amyrin, cyclo-
artenol, lupeol, and 24-methylenecycloartanol [38]. Triterpe-
noids are known to stimulate insulin release from pancreas
and reduces oxidative stress thus can be effective in man-
agement of diabetes and related complications [39,40].
Phenolic compounds are one of the largest and most
ubiquitous groups of plant metabolites. Natural antioxidants
mainly come from plants in the form of phenolic compounds
such as flavonoids and phenolic acids. In vitro and in vivoeffect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
Table 3 e Effect of alcohol (PA) and hydroalcohol (PHA) extracts of Paeonia emodi Royale roots on lipid profile in diabetic-nephropathy Wistar rats.a
Parameters TC (mg/dL) TG (mg/dL) LDL (mg/dL) VLDL (mg/dL) HDL (mg/dL)
Groups 30th day 75th day 30th day 75th day 30th day 75th day 30th day 75th day 30th day 75th day
Normal 103.5 ± 2.75 103.6 ± 2.02 72.44 ± 2.06 71.38 ± 1.46 33.00 ± 2.20 32.96 ± 2.47 33.07 ± 0.94 32.59 ± 0.66 56.09 ± 0.63 56.44 ± 0.54
Diabetic
control
250.4 ± 2.54a* 295.8 ± 2.49a* 161.72 ± 3.27a* 203.26 ± 1.12a* 187.26 ± 2.31a* 229.13 ± 2.72a* 73.84 ± 1.49a* 92.81 ± 0.51a* 30.86 ± 0.424a* 26.07 ± 0.329a*
PA 100 mg/kg 268.6 ± 3.0b*d** 169.7 ± 0.501b*d* 154.64 ± 1.563 100.29 ± 1.057b*d* 210.98 ± 2.72b*d* 113.65 ± 1.61b*d* 70.61 ± 0.711 45.97 ± 0.480b*d* 31.36 ± 0.787b* 26.24 ± 0.411b*d*
PA 200 mg/kg 251.1 ± 3.020c** 134.4 ± 1.055b*c* 153.19 ± 1.362b*** 90.09 ± 0.773b*c* 193.27 ± 3.23c* 76.32 ± 1.38b*c* 69.95 ± 0.619 43.13 ± 0.351b*c* 26.75 ± 0.765b** 36.04 ± 0.775b*c*
PA 400 mg/kg 241.5 ± 2.141c* 104.85 ± 0.789b*c*d* 151.68 ± 1.723b*** 71.01 ± 2.0153b*c*d* 184.96 ± 2.85c* 47.08 ± 2.26b*c*d* 69.26 ± 0.783b*** 32.42 ± 0.916b*c*d* 27.19 ± 0.553b* 40.05 ± 0.747b*c*d**
PHA 100 mg/kg 260.5 ± 3.93 162.29 ± 0.801b*d* 155.61 ± 3.049 108.68 ± 1.363b*d* 198.08 ± 4.85 106.34 ± 2.13b*d* 71.05 ± 1.386 49.62 ± 0.620b*d* 26.29 ± 0.745b* 43.57 ± 0.579b*d**
PHA 200 mg/kg 246.56 ± 2.026 142.39 ± 0.724b*c* 162.04 ± 2.397 97.55 ± 1.177b*c* 201.26 ± 1.68b*** 83.46 ± 1.49b*c* 73.99 ± 1.090 44.54 ± 0.535b*c* 25.88 ± 0.918b** 34.21 ± 0.570b*c**
PHA 400 mg/kg 250.36 ± 2.369d*** 105.43 ± 0.655b*c*d* 161.59 ± 1.577 81.23 ± 0.825b*c*d* 186.71 ± 2.69d*** 44.87 ± 1.56b*c*d* 73.78 ± 0.717 37.09 ± 0.375b*c*d* 26.83 ± 0.784b** 39.41 ± 0.810b*c*d*
Glimepride10
mg/kg
252.2 ± 2.91 102.5 ± 1.33b* 158.89 ± 2.24 71.68 ± 2.02b* 189.74 ± 3.19 34.39 ± 1.57b* 72.55 ± 1.02 32.73 ± 0.92b* 30.68 ± 0.703 53.81 ± 0.295b*
* p < 0.001.
** p < 0.01.
*** p < 0.05.
a ¼ versus control, b ¼ versus diabetic control, c ¼ versus P. emodi extract 100 mg/kg, d ¼ versus P. emodi extract 200 mg/kg.
a Each group (n ¼ 6) represents mean ± standard error of the mean. Data were analyzed by using one-way analysis of variance followed by Tukey's multiple test.
Table 4 e Effect of alcohol (PA) and hydroalcohol (PHA) extracts of Paeonia emodi Royale roots on level of antioxidant enzymes and lipid peroxidation (TBARS) in diabetic-
nephropathy Wistar rats.a
Parameters SOD (U/mg protein) GSH (mM/mg protein) TBARS (nmol/mg protein)
Groups Kidney Pancreas Liver Kidney Pancreas Liver Kidney Pancreas Liver
Normal 4.87 ± 0.083 4.17 ± 0.298 3.67 ± 0.096 74.93 ± 0.621 69.45 ± 0.289 66.21 ± 0.476 0.55 ± 0.01 0.46 ± 0.011 0.41 ± 0.005
Diabetic control 1.23 ± 0.049a* 1.15 ± 0.058a* 1.06 ± 0.045a* 38.60 ± 0.481a* 41.90 ± 0.347a* 45.53 ± 0.482a* 2.98 ± 0.017a* 2.71 ± 0.068a* 2.48 ± 0.066a*
PA 100 mg/kg 2.048 ± 0.022b*d* 1.32 ± 0.017d** 1.15 ± 0.020d* 43.34 ± 0.548b*d* 43.21 ± 0.297d* 48.55 ± 0.336b*d* 2.46 ± 0.033b*d* 1.84 ± 0.019b*d* 1.47 ± 0.015b*d***
PA 200 mg/kg 2.81 ± 0.036b*c* 2.20 ± 0.023b*c** 2.06 ± 0.023b*c* 53.23 ± 0.761b*c* 50.96 ± 0.625b*c* 53.61 ± 0.494b*c* 1.93 ± 0.011b*c* 1.33 ± 0.008b*c* 1.31 ± 0.022b*c***
PA 400 mg/kg 3.76 ± 0.026b*c*d* 3.08 ± 0.007b*c*d** 3.08 ± 0.012b*c*d* 64.71 ± 0.407b*c*d* 57.80 ± 0.316b*c*d* 57.33 ± 0.237b*c*d* 1.27 ± 0.021b*c*d* 1.10 ± 0.023c*d* 1.12 ± 0.007b**c*d**
PHA 100 mg/kg 2.17 ± 0.015b*d* 1.49 ± 0.025d* 1.28 ± 0.013d* 46.69 ± 0.378b*d* 45.15 ± 0.359b*d* 48.11 ± 0.160b*d* 2.19 ± 0.011b*d* 1.74 ± 0.013b*d* 1.42 ± 0.009b*d*
PHA 200 mg/kg 3.01 ± 0.019b*c* 2.44 ± 0.010b*c* 2.24 ± 0.008b*c* 56.61 ± 0.286b*c* 53.59 ± 0.347b*c* 51.86 ± 0.221b*c* 1.83 ± 0.020b*c* 1.21 ± 0.005b*c* 1.22 ± 0.005b*c*
PHA 400 mg/kg 3.98 ± 0.017b*c*d* 3.21 ± 0.019b*c*d** 3.15 ± 0.010b*c*d* 65.38 ± 0.282b*c*d* 56.88 ± 0.253b*c*d* 59.04 ± 0.086b*c*d* 1.84 ± 0.020c*d* 1.01 ± 0.02c*d* 0.97 ± 0.012c*d*
Glimepride10 mg/kg 3.86 ± 0.018b* 4.03 ± 0.148b* 3.63 ± 0.110b* 67.83 ± 0.535b* 60.77 ± 0.375b* 61.26 ± 0.350b* 1.19 ± 0.03b* 0.98 ± 0.020b* 0.92 ± 0.031b*
* p < 0.001.
** p < 0.01.
*** p < 0.05.
a¼ versus control, b¼ versus diabetic control, c¼ versus P. emodi extract 100mg/kg, d¼ versus P. emodi extract 200mg/kg; GSH¼ glutathione; SOD¼ superoxide dismutase, TBARS¼ thiobarbituric acid
reactive substances.
a Each group (n ¼ 6) represents mean ± standard error of the mean. Data were analyzed by using one-way analysis of variance followed by Tukey's multiple test.
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Figure 4 e Effect of alcohol (PA) and hydroalcohol (PHA) extracts of Paeonia emodi Royale roots on level of advanced glycation
end-products. Data were analyzed by using one-way analysis of variance followed by Tukey's multiple test. Values are
represented as mean ± standard error of the mean (n ¼ 6). * p < 0.001. ** p < 0.01. *** p < 0.05. a ¼ versus control, b ¼ versus
diabetic control, c ¼ versus standard.
Figure 5 e Histopathological changes in kidney of normal and treated rats (hematoxylin and eosin 10£); “a” shows the
glomerulus. (A) Normal; (B) diabetic nephropathy control; (C) standard; (D) treated with 100 mg/kg alcohol extract of Paeonia
emodi Royale roots (PA); (E) PA 200mg/kg; (F) PA 400mg/kg; (G); treated with 100mg/kg hydroalcohol extract of Paeonia emodi
Royale roots (PHA); (H) PHA 200 mg/kg; and (I) PHA 400 mg/kg.
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Figure 6 e Histopathological changes in pancreatic islet of normal and treated rats (hematoxylin and eosin; magnification
10£); “a” shows the liver central vein. (A) Normal; (B) diabetic nephropathy control; (C) standard; (D) treated with 100 mg/kg
alcohol extract of Paeonia emodi Royale roots (PA); (E) PA 200 mg/kg; (F) PA 400 mg/kg; (G); treated with 100 mg/kg
hydroalcohol extract of Paeonia emodi Royale roots (PHA); (H) PHA 200 mg/kg; and (I) PHA 400 mg/kg.
j o u r n a l o f f o o d and d ru g an a l y s i s x x x ( 2 0 1 6 ) 1e1 310experiments have shown that phenolic acids exhibit
powerful effects on biological responses by scavenging free
radicals and eliciting antioxidant capacity [41]. Phenolic
compounds present in P. emodi in previous studies include
ethyl gallate, methyl grevillate [10], benzoic acid, 3-hydroxy
benzoic acid [8], 4-hydroxy benzoic acid, gallic acid, and
methyl gallate [14]. Flavonoids and other phenolic com-
pounds are known to reduce oxidative stress, reduce necro-
sis, and regenerate b-cells [42]. Phenolic compounds are
potent free radical scavengers that increase antioxidant
enzyme level and reduced lipid peroxidation Thus, the
presence of these secondary metabolites may prove benefi-
cial for counteracting the complications associated with
diabetes.
Administration of STZ leads to chronic hyperglycemia
indicated by elevated fasting blood glucose level in experi-
mental animals due to pancreatic b cell damage, which is also
suggested by increase in the levels of HbA1c%, whereas
administration of PA and PHA resulted in a significant
reduction of the fasting blood glucose level as compared to
diabetic rats. Moreover, induction of diabeteswith STZ-NAD is
associated with the characteristic loss of body weight, which
is mainly due to increased muscle wasting [43] and loss ofPlease cite this article in press as: Kishore L, et al., Nephroprotective
products and oxidative stress in streptozotocinenicotinamide induce
http://dx.doi.org/10.1016/j.jfda.2016.08.009tissue proteins [44]. Oral administration of PA and PHA
improved the body weight in diabetic rats by reversing the
muscle wasting and protein loss. Thismay be achieved via the
inhibition of hepatic gluconeogenesis and glucose output
from the liver, which is accompanied by the suppression of
lipolysis in adipose tissue [45].
Diabetic rats were found to have significantly increased
level of plasma glucose, total cholesterol, triglycerides, LDL-
cholesterol, and VLDL-cholesterol, but decreased plasma
HDL-cholesterol and insulin levels [46]. Similarly, in our study,
significant dyslipidemiawas observed in experimental animals
and administration of PA and PHA significantly reduced lipid
levels. Besides reducing lipid levels, PA and PHA effectively
increased HDL-cholesterol level. The antihyperglycaemic ef-
fect of PA and PHA and improved diabetic state may lead to a
reduction in the concentration of VLDL and consequently the
LDL level [47]. A study by Zargar et al [21] on antihyperlipidemic
effect of P. emodi supported our present study.
Moreover, high glucose-induced renal damage is associ-
ated with excessive production of ROS under hyperglycemic
conditions [48]. ROS can react with polyunsaturated fatty
acids leading to lipid peroxidation and irreversible tissue
damage [42]. It is found that high glucose-induced renaleffect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
Figure 7 e Histopathological changes in Liver of normal and treated rats (hematoxylin and eosin 10£); “a” shows b-cells. (A)
Normal; (B) diabetic nephropathy control; (C) standard; (D) treated with 100 mg/kg alcohol extract of Paeonia emodi Royale
roots (PA); (E) PA 200 mg/kg; (F) PA 400 mg/kg; (G); treated with 100 mg/kg hydroalcohol extract of Paeonia emodi Royale roots
(PHA); (H) PHA 200 mg/kg; and (I) PHA 400 mg/kg.
j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e1 3 11damage is associated with excessive production of ROS under
hyperglycemic conditions [48]. Typical markers of oxidative
stress have been reported in both diabetic humans and ani-
mals, including increased ROS, malondialdehyde, and
reduced levels of antioxidants [49]. Induction of diabetes in
the present study led to significant elevation of malondialde-
hyde and a reduction of SOD and GSH in the kidneys,
pancreas, and liver. Administration of PA and PHA amelio-
rated oxidative damage in DN rats via increasing level of
antioxidant enzymes and reduced LPO. The effectiveness of P.
emodi against oxidative stress is widely recognized and has
been discussed in other studies [21,50,51], which supported
our present study.
Renal damage is evident with increase in UAE, serum
creatinine, and BUN indicating reduced creatinine and urea
clearance. Similar structural changes were found in the pre-
sent study. Treatment of DN rats with PA and PHA effectively
reduced the levels of urea, uric acid, creatinine and BUN
indicating their increased clearance from kidney. Moreover,
the untreated diabetic rats showed signs of diabetic ne-
phropathy, including the increased urine volume, reduced
level of creatinine in urine and creatinine clearance. Admin-
istration of PA and PHA for 45 days significantly decreased the
level of all these parameters. At the onset of diabetes, thePlease cite this article in press as: Kishore L, et al., Nephroprotective
products and oxidative stress in streptozotocinenicotinamide induce
http://dx.doi.org/10.1016/j.jfda.2016.08.009kidney grows large and the glomerular filtration rate becomes
disturbed [52].
Formation of AGEs facilitated by oxidative stress is the
product of the reaction between carbohydrates and the free
amino group of proteins [53]. AGEs have been implicated to
play key roles in the pathogenesis of DN by stimulating cyto-
kine and growth factor synthesis leading to extracellular
matrix accumulation in kidneys [54]. Treatment of DN rats
with PA and PHA effectively reduced the levels of AGEs in the
kidney.
DN is characterized by a series of renal structure abnor-
malities including basementmembrane thickening, mesangial
expansion, glomerulosclerosis, and tubulointerstitial fibrosis
[55]. In the present study, histopathological observations of
kidney showed glomeruli with mesangiocapillary prolifera-
tion. Messangial expansion is a crucial structural change
leading to loss of renal function in diabetes. Liver showed
perivenular inflammatory collection. The ultrastructure of
diabetic pancreas showed considerable reduction in the islets
of Langerhans and depleted islets [56]. Similar structural
changes in pancreas were found in the present study. Oral
administration of PA and PHA significantly improved the his-
tological alterations induced by STZ-NAD, which could be
attributed to its antioxidant properties of the plant.effect of Paeonia emodi via inhibition of advanced glycation end
d diabetic nephropathy, Journal of Food and Drug Analysis (2016),
j o u r n a l o f f o o d and d ru g an a l y s i s x x x ( 2 0 1 6 ) 1e1 3125. Conclusion
It can be concluded that PA and PHA showed protective effect
against DN, since they exhibited beneficial effects on the blood
glucose level, associated biomarkers of DN and AGEs in
kidney.Conflicts of interest
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